Limits...
Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.

Horinaka A, Sakurai D, Ihara F, Makita Y, Kunii N, Motohashi S, Nakayama T, Okamoto Y - Cancer Sci. (2016)

Bottom Line: However, the effect on the host immune system, especially on invariant NKT (iNKT) cells with potent anti-tumor activity, remains unclear.However, iNKT cell activation upon α-galactosylceramide (αGalCer) stimulation was not affected by the presence or absence of CD15+ G-MDSC.Cancer immunotherapy designed to enhance the antitumor activity of iNKT cells by stimulation with αGalCer may remain effective in the presence of G-MDSC.

View Article: PubMed Central - PubMed

Affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

Show MeSH

Related in: MedlinePlus

Percentage of granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) in peripheral blood cells and the correlation with the percentage of peripheral lymphocytes. (a) The percentage of HLA‐DR− Lin− CD15+ G‐MDSC from healthy donors and patients with pleomorphic adenoma, thyroid papillary carcinoma and head and neck squamous cell carcinoma (HNSCC). (b–f) The correlation between the percentage of G‐MDSC and the percentage of circulating lymphocytes subsets in HNSCC patients. (g) The percentage of HLA‐DR− Lin− CD14− CD15+ G‐MDSC at pre‐standard and post‐standard therapy in HNSCC patients. *P < 0.05, **P < 0.01.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814259&req=5

cas12866-fig-0003: Percentage of granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) in peripheral blood cells and the correlation with the percentage of peripheral lymphocytes. (a) The percentage of HLA‐DR− Lin− CD15+ G‐MDSC from healthy donors and patients with pleomorphic adenoma, thyroid papillary carcinoma and head and neck squamous cell carcinoma (HNSCC). (b–f) The correlation between the percentage of G‐MDSC and the percentage of circulating lymphocytes subsets in HNSCC patients. (g) The percentage of HLA‐DR− Lin− CD14− CD15+ G‐MDSC at pre‐standard and post‐standard therapy in HNSCC patients. *P < 0.05, **P < 0.01.

Mentions: The percentage of HLA‐DR− Lin− CD15+ G‐MDSC was significantly increased in patients with HNSCC compared with pleomorphic adenoma patients or healthy donors (Fig. 3a). No correlation was detected between the proportion of G‐MDSC and the lymphocyte subsets, including CD19+, CD56+ and Vα24+ Vβ11+ cells (Fig. 3b,d–f). However, a significant inverse correlation was detected between the ratio of HLA‐DR− Lin− CD14− CD15+ G‐MDSC and CD3+ cells (P < 0.01; Fig. 3c). To examine the correlation between MDSC and the clinical course, the ratio of G‐MDSC in five HNSCC patients with a high percentage (>1%) of G‐MDSC before treatment were counted again after 2 months of treatment. All five patients had a complete response after treatment, with significant decreases in the frequencies of circulating G‐MDSC detected following standard treatments (one patient treated with surgery alone, 2 with surgery and chemoradiotherapy and 2 with chemoradiotherapy alone; Fig. 3g). The ratio of CD3+ cells and Vα24+ Vβ11+ cells in the five patients were not significantly changed after treatment (data not shown).


Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.

Horinaka A, Sakurai D, Ihara F, Makita Y, Kunii N, Motohashi S, Nakayama T, Okamoto Y - Cancer Sci. (2016)

Percentage of granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) in peripheral blood cells and the correlation with the percentage of peripheral lymphocytes. (a) The percentage of HLA‐DR− Lin− CD15+ G‐MDSC from healthy donors and patients with pleomorphic adenoma, thyroid papillary carcinoma and head and neck squamous cell carcinoma (HNSCC). (b–f) The correlation between the percentage of G‐MDSC and the percentage of circulating lymphocytes subsets in HNSCC patients. (g) The percentage of HLA‐DR− Lin− CD14− CD15+ G‐MDSC at pre‐standard and post‐standard therapy in HNSCC patients. *P < 0.05, **P < 0.01.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814259&req=5

cas12866-fig-0003: Percentage of granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) in peripheral blood cells and the correlation with the percentage of peripheral lymphocytes. (a) The percentage of HLA‐DR− Lin− CD15+ G‐MDSC from healthy donors and patients with pleomorphic adenoma, thyroid papillary carcinoma and head and neck squamous cell carcinoma (HNSCC). (b–f) The correlation between the percentage of G‐MDSC and the percentage of circulating lymphocytes subsets in HNSCC patients. (g) The percentage of HLA‐DR− Lin− CD14− CD15+ G‐MDSC at pre‐standard and post‐standard therapy in HNSCC patients. *P < 0.05, **P < 0.01.
Mentions: The percentage of HLA‐DR− Lin− CD15+ G‐MDSC was significantly increased in patients with HNSCC compared with pleomorphic adenoma patients or healthy donors (Fig. 3a). No correlation was detected between the proportion of G‐MDSC and the lymphocyte subsets, including CD19+, CD56+ and Vα24+ Vβ11+ cells (Fig. 3b,d–f). However, a significant inverse correlation was detected between the ratio of HLA‐DR− Lin− CD14− CD15+ G‐MDSC and CD3+ cells (P < 0.01; Fig. 3c). To examine the correlation between MDSC and the clinical course, the ratio of G‐MDSC in five HNSCC patients with a high percentage (>1%) of G‐MDSC before treatment were counted again after 2 months of treatment. All five patients had a complete response after treatment, with significant decreases in the frequencies of circulating G‐MDSC detected following standard treatments (one patient treated with surgery alone, 2 with surgery and chemoradiotherapy and 2 with chemoradiotherapy alone; Fig. 3g). The ratio of CD3+ cells and Vα24+ Vβ11+ cells in the five patients were not significantly changed after treatment (data not shown).

Bottom Line: However, the effect on the host immune system, especially on invariant NKT (iNKT) cells with potent anti-tumor activity, remains unclear.However, iNKT cell activation upon α-galactosylceramide (αGalCer) stimulation was not affected by the presence or absence of CD15+ G-MDSC.Cancer immunotherapy designed to enhance the antitumor activity of iNKT cells by stimulation with αGalCer may remain effective in the presence of G-MDSC.

View Article: PubMed Central - PubMed

Affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

Show MeSH
Related in: MedlinePlus